Biogen ’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA

CAMBRIDGE, Mass.--(BUSINESS WIRE) October 28, 2016 -- Biogen (NASDAQ: BIIB) today announced that its New Drug Application (NDA) for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), has been accepted by the U.S. Food and...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news